Skip to main content
main-content

The independent medical news service

Breast cancer

21-01-2022 | Oncology | News | Article

ASCO/Ontario Health guideline on bone-modifying agents in breast cancer updated

Click through to find out what has changed

21-01-2022 | Oncology | News | Article

Capecitabine-containing adjuvant regimen improves early breast cancer OS

Adjuvant treatment with a capecitabine-containing chemotherapy regimen could improve the overall survival of patients with early breast cancer, suggest long-term follow-up data from the phase 3 FinXX trial.

14-01-2022 | Oncology | News | Article

10-year cumulative false–positive mammography risk around 20%

Just under one in five women will experience at least one false–positive result during 10 years of biennial breast screening, population-based data from Norway show.

10-01-2022 | Oncology | News | Article

GnRHa protects ovarian function during chemotherapy for breast cancer

Adding a gonadotropin-releasing hormone analog to cyclophosphamide-containing chemotherapy significantly reduces the risk for premature ovarian insufficiency in premenopausal women with breast cancer, Chinese research shows.

04-01-2022 | Oncology | News | Article

HER2CLIMB final OS analysis confirms tucatinib HER2-positive breast cancer benefit

The addition of tucatinib to trastuzumab plus capecitabine continues to confer an overall survival benefit in advanced HER2-positive breast cancer over longer follow-up, show phase 2 data.

21-12-2021 | Oncology | News | Article

NOS inhibitor shows potential for TNBC treatment

The pan-nitric oxide signaling inhibitor NG-monomethyl-l-arginine in combination with taxane merits further investigation in the locally advanced or metastatic triple-negative breast cancer setting, say researchers.

14-12-2021 | Oncology | News | Article

Anthracycline addition to taxane supported for early breast cancer

A patient-level meta-analysis has demonstrated a significant reduction in the risk for invasive recurrence with the use of an anthracycline alongside taxane-based chemotherapy for the treatment of early-stage breast cancer.

14-12-2021 | Oncology | News | Article

PADA-1 shows clinical utility of blood ESR1 mutation monitoring

Women with hormone receptor-positive, HER2-negative metastatic breast cancer benefit from switching from an aromatase inhibitor to fulvestrant in palbociclib combination therapy when an ESR1 mutation is detected without disease progression, phase 3 PADA-1 trial data show.

10-12-2021 | Oncology | News | Article

ctDNA target mutations show prognostic value in advanced breast cancer

Circulating tumor DNA target mutations may represent a promising prognostic biomarker among women receiving first-line ribociclib plus letrozole for hormone receptor-positive, HER2-negative advanced breast cancer, research suggests.

10-12-2021 | Oncology | News | Article

Dual checkpoint inhibition shows promise for highly mutated HER2-negative MBC

Dual checkpoint inhibition with nivolumab plus ipilimumab may be a promising treatment option for people with HER2-negative metastatic breast cancer and high tumor mutational burden, phase 2 NIMBUS study data show.

09-12-2021 | Oncology | News | Article

Meta-analysis supports AIs in premenopausal breast cancer patients receiving ovarian suppression

Aromatase inhibitors significantly reduce the risk for breast cancer recurrence relative to tamoxifen in premenopausal women treated with ovarian function suppression, suggests a patient-level meta-analysis.

09-12-2021 | Oncology | News | Article

Novel SERD boosts PFS of patients with ER-positive, metastatic breast cancer

A phase 3 trial has demonstrated a significant progression-free survival benefit with the oral SERD elacestrant relative to standard of care in pretreated patients with estrogen receptor-positive, HER2-negative metastatic breast cancer.

08-12-2021 | Oncology | News | Article

Appropriate framework must guide targeted therapy for metastatic breast cancer

Multigene sequencing identifies patients with metastatic breast cancer who will benefit from targeted therapy, but its use must be driven by a framework of actionability, show data presented at the 2021 San Antonio Breast Cancer Symposium.

08-12-2021 | Oncology | News | Article

​​​​​​​No benefit of adjuvant metformin in HR-positive, negative early breast cancer

Adjuvant treatment with metformin does not improve the outcomes of patients with HR-positive or negative early breast cancer, suggest trial data presented at the 2021 San Antonio Breast Cancer Symposium.

01-12-2021 | Oncology | News | Article

UK PROSPER trial backs early exercise after breast cancer surgery

Early, structured exercise reduces upper limb disability and improves physical quality of life compared with usual care among women at risk for postoperative complications following breast cancer surgery, UK PROSPER study data show.

26-11-2021 | Oncology | News | Article

Breast cancer-related vertebral fracture risk characterized

Physicians should be aware of the likelihood of pathologic etiology in advanced breast cancer patients who have sustained fractures of the vertebrae, say US researchers.

22-11-2021 | Oncology | News | Article

Cancer patterns mapped out in Li-Fraumeni syndrome

People with Li-Fraumeni syndrome, who carry pathogenic or likely pathogenic germline TP53 variants, are 24 times more likely to develop cancer than people from the general population, research shows.

11-11-2021 | Oncology | News | Article

More support for integrating geriatric assessment-guided management into oncology care

Incorporating geriatric assessment-guided management into the care of older patients receiving anticancer therapy could reduce the risk for treatment toxicity and falls as well as polypharmacy, suggests a cluster randomized controlled trial.

01-11-2021 | Oncology | News | Article

Multigene panel testing ‘may be appropriate’ for invasive lobular carcinoma

Germline pathogenic variants in five hereditary cancer genes, including BRCA2, are significantly associated with invasive lobular carcinoma risk, US study findings indicate.

28-10-2021 | Oncology | News | Article

Physicians misjudge breast cancer genetic screening barriers for African Americans

A survey of US oncologists and physicians has shown that their perceived barriers toward genetic counseling and testing for breast cancer vary by patients' race.

Image Credits